8/7/2023 0 Comments Bryce anderson and associatesRadiographic and serum marker reductions were observed among ten patients with metastatic castration resistant prostate cancer, four of whom survived two years or longer. Durable partial responses were induced in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and thymoma. Nine (17%) of the 54 efficacy evaluable patients achieved progression-free survival ≥6 months. The recommended phase 2 dose was determined to be 360 mg/m 2. Grade 3 events were experienced by 18 patients (27%), with no grade 4-5 events observed. Treatment-related adverse events included fatigue (23 patients, 35%), nausea (16 patients, 24%), and peripheral neuropathy (14 patients, 21%). This study is registered at, number NCT02266745, with the dose-escalation portion of the study closed.īetween July 7th, 2014 and September 18th, 2018, 66 heavily pre-treated patients (median 4 prior lines, IQR 2-6) were enrolled and treated across 11 doses (12-420 mg/m 2). Patients receiving ≥1 dose of PT-112 were included in the safety and pharmacokinetic analyses, with the exploratory efficacy analysis including patients receiving ≥1 dose at 125 mg/m 2. Eligibility criteria included: age ≥18 years, Eastern Collaborative Oncology Group (ECOG) Performance Status of 0-1, and disease evaluable by Response Evaluation Criteria in Solid Tumours (RECIST) v1♱ or by informative tumour markers. The primary objective was to assess safety and pharmacokinetics, and to identify a recommended phase 2 dose (RP2D). Patients with progressing, advanced solid tumours received PT-112 intravenously (1 h) on days 1, 8, 15 of a 28-day cycle in an open-label, multi-centre 3 + 3 dose-escalation trial, conducted at four US research sites. This is the first-in-human study of PT-112 monotherapy, exploring its safety and efficacy in a patient population where standard of care therapies were exhausted and novel treatment options are needed. PT-112 also associates with bone (osteotropism), likely driven by its pyrophosphate moiety. He received an undergraduate degree from the University of New Hampshire and an MBA from Harvard Business School.PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. (a subsidiary of AvalonBay Communities, Inc.), Executive Chairman at Invitation Homes, Inc., Partner-Northeast Group at Trammell Crow Residential Co., Member of World Presidents' Organization, Member of National Association of Real Estate Investment Trusts, Inc., Chairman at National Multifamily Housing Council, Chairman of National Association of Home Builders and Member of Young Presidents' Organization, Inc. and SVP-Development, Acquisitions & Construction at Avalon Properties, Inc. Blair held the position of Chairman & Chief Executive Officer of AvalonBay Communities, Inc. and Regency Centers LP and Manager at Harborview Associates LLC. Blair is also on the board of Regency Centers Corp. and Executive Chairman at Invitation Homes LP. Blair is a businessperson who has been at the helm of 8 different companies and currently holds the position of Non-Executive Chairman of PulteGroup, Inc., Chairman for Preeminent Holdings, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |